Lifeline BioTechnologies, Inc. Forms Subsidiary First Warning Systems(TM), Inc. For Detection Of Breast Cancer
Jim Holmes, Lifeline’s CEO stated, “Now that the First Warning Systems™ interpretative software patent has been filed, a new Lifeline Biotechnologies wholly owned subsidiary, First Warning Systems, Inc. has been created. First Warning Systems™ will afford the concentrated effort to move towards commercialization of the process that assists in the early detection of breast cancer. Our system of classification of thermal abnormalities assists in the early detection of breast cancer, often before morphological changes are obvious. This is cutting edge technology and holds the potential of revolutionizing early breast cancer detection, at stages of the development of the cancer when it is much more probable that a cure of the disease can be successful.”
About Lifeline Biotechnologies, Inc:
Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System™, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: Clinical trials (if required) and filing and receiving a 510(k) from the FDA, and the product is successfully established in the marketplace.
Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com
Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company’s product and regulatory and shareholder approval for anticipated actions.
Contact:
for Lifeline Biotechnologies, Inc. e-media Direct, Inc. Investor Relations, 866-284-2835 info@e-mediadirect.com
Source: Lifeline Biotechnologies, Inc.